Table 1 Baseline characteristics of guselkumab-randomized patients

Age, years

45.9 (11.5)

44.9 (11.9)

45.4 (11.7)

Male sex, n (%)

142 (58%)

129 (52%)

271 (55%)

Race, n (%)

 White

 Asian

242 (99%)

3 (1%)

240 (97%)

8 (3%)

482 (98%)

11 (2%)

BMI, kg/m²

 Normal (< 18.5–<25 kg/m²), n (%)

 Overweight (25–<30 kg/m²), n (%)

 Obese (≥ 30 kg/m²), n (%)

29.1 (5.9)

66 (26.9%)

83 (33.9%)

96 (39.2%)

28.7 (6.3)

74 (29.8%)

82 (33.1%)

92 (37.1%)

28.9 (6.1)

140 (28.4%)

165 (33.5%)

188 (38.1%)

PsA duration, years

5.5 (5.9)

5.1 (5.5)

5.3 (5.7)

SJC (0–66)

12.9 (7.8)

11.7 (6.8)

12.3 (7.4)

TJC (0–68)

22.4 (13.5)

19.8 (11.9)

21.1 (12.8)

HAQ-DI score (0–3)

1.2 (0.6)

1.3 (0.6)

1.3 (0.6)

PtGA– arthritis VAS (0–10 cm)

6.4 (1.9)

6.5 (1.9)

6.5 (1.9)

Pt Pain VAS (0–10 cm)

6.2 (2.0)

6.3 (2.0)

6.2 (2.0)

PASI score (0–72)

10.8 (11.7)

9.7 (11.7)

10.2 (11.7)

Enthesitis, n (%)

 LEI score

170 (69%)

3.0 (1.7)

158 (64%)

2.6 (1.5)

328 (67%)

2.8 (1.6)

FACIT-Fatigue score

30.8 (9.6)

29.3 (9.9)

30.0 (9.8)

Medical history of depression, n (%)

4 (1.6%)

4 (1.6%)

8 (1.6%)

Suicidal ideation (eC-SSRS), n (%)*

3 (1.2%)

6 (2.4%)

9 (1.8%)

Medical history of fibromyalgia, n (%)

2 (0.8%)

1 (0.4%)

3 (0.6%)